Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Overexpression of HER-2/neu in Patients with Prostatic Adenocarcinoma

  • Zahir, Shokouh Taghipour (Department of Pathology, Faculty of Cedicine, Shahid Sadoughi University of Medical Sciences) ;
  • Tafti, Hamid Fallah (Department of Cancer Research Center, Faculty of Cedicine, Shahid Sadoughi University of Medical Sciences) ;
  • Rahmani, Koorosh (Department of Cancer Research Center, Faculty of Cedicine, Shahid Sadoughi University of Medical Sciences)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Prostatic adenocarcinoma is one of the main causes of cancer death, and its timely diagnosis and preventing its progression dramatically helps improve life indexes. Given the high disease recurrence rate, today, research is more inclined toward exploring causes of recurrence and development, and innovation of modern treatment methods. Several studies have explored over-expression of human epidermal growth factor receptor 2 (HER-2/neu) in prostatic cancer so far, with different results. Thus, it was decided to investigate HER-2/neu overexpression in patients with prostatic adenocarcinoma in Iran. Materials and Methods: A sample size of 40 patients with prostate cancer entered the study, using a cross-sectional, non-randomized sampling method. Parameters studied included patient age at surgery, Gleason score, serum prostatic specific antigen (PSA) before surgery, and positive sample rate after immunohistochemical staining to investigate HER-2/neu overexpression. Results: In terms of HER-2/neu receptor staining rate, of 40 slides, 16 (40%) scored 0, 13 (32.5%) 1+, 7 (17.5%) 2+, and 4 (10%) 3+. In total 27.5% of slides showed HER-2/neu overexpression. In terms of age, an inverse correlation was found (-0.181), but without significance (p=0.263). In terms of serum PSA, the correlation coefficient was 0.449 (p=0.004). With respect to Gleason score, the coefficient was 0.190 (p=0.240). Conclusions: In this study, HER-2/neu overexpression occurred in 27.5% of prostate cancer cases, which is a relatively high figure, compared to similar studies elsewhere. While, we failed to reveal any relationship between HER-2/neu expression status with progression and prognosis of disease, it was demonstrated that the serum PSA level was significantly higher in cases with increased receptor expression.

Keywords

References

  1. Ali Nahit Sendur M, Aksoy S, Ozdemir NY, Zengin N, Altundag K (2012 ).What is the mechanism of progression with Trastuzumab treatment - escape or resistance? Asian Pac J Cancer Prev, 13, 5915-6. https://doi.org/10.7314/APJCP.2012.13.11.5915
  2. Baek KH, Hong ME, Jung YY, et al (2012). Correlation of AR, EGFR, and HER-2 expression levels in prostate cancer: Immunohistochemical analysis and chromogenic in situ hybridization. Cancer Res Treat, 44, 50-6. https://doi.org/10.4143/crt.2012.44.1.50
  3. Bai Q , Chen F, Qi J, et al (2007). Relationship between HER-2/neu over-expression and androgen independent prostate cancer. Zhonghua Nan Ke Xue, 13,414-6.
  4. Begnami MD, Fukuda E, Fregnani JH, et al (2011). Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome . J Clin Oncol, 1, 3030-6.
  5. Calvo BF, Levine AM, Marcos M, et al (2003). Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res, 9, 1087-92.
  6. Carrion-Salip D, Panosa C, Menendez JA (2012). Androgenindependent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol, 41, 1128-38.
  7. Di Lorenzo G, Autorino R, De Laurentiis M, et al (2004). HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori, 90, 163-70.
  8. Gates JD, Carmichael MG, Benavides LC, et al (2009). Long term follow up assessment of a HER-2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J Coll Surg, 208, 193-201. https://doi.org/10.1016/j.jamcollsurg.2008.10.018
  9. Hsing AW, Tsao L, Devesa SS (2000). International trends and patterns of prostate cancer incidence and mortality. Int J Cancer, 85, 60-67. https://doi.org/10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B
  10. Lara PN, Meyers FJ, Gray CR, et al (2002). HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Cancer, 94, 2584-9. https://doi.org/10.1002/cncr.10526
  11. Liu AN, Sun P, Liu JN, et al (2012). Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer. Asian Pac J Cancer Prev, 13, 1197-201. https://doi.org/10.7314/APJCP.2012.13.4.1197
  12. Loeb S, Kettermann A, Ferrucci L, et al (2008). PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the baltimore longitudinal study of aging. Eur Urol, 54, 1073-80. https://doi.org/10.1016/j.eururo.2008.06.076
  13. Montironi R, Mazzucchelli R, Barbisan F, et al (2006). HER-2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cyst prostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol, 37, 1137-44. https://doi.org/10.1016/j.humpath.2006.04.004
  14. Muhammadnejad S, Muhammadnejad A, Haddadi M (2013). Correlation of micro vessel density with nuclear pleomorphism, mitotic count and vascular invasion in breast and prostate cancers at preclinical and clinical levels. Asian Pac J Cancer Prev, 14, 63-68. https://doi.org/10.7314/APJCP.2013.14.1.63
  15. Nath A, Singh JK, Vendan SE, Priyanka, Sinha S (2012). Elevated level of prostate specific antigen among prostate cancer patients and high prevalence in the Gangetic Zone of Bihar, India. Asian Pac J Cancer Prev, 14, 63-8.
  16. Neto AS, Tobias-Machado M, Wroclawski ML (2010). Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu). Tumori, 96, 645-9.
  17. Neto AS, Tobias-Machado M, Wroclawski ML, et al (2010). Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol, 184, 842-50. https://doi.org/10.1016/j.juro.2010.04.077
  18. Shariat SF, Bensalah K, Karam JA, et al (2007). Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res, 13, 5377-84. https://doi.org/10.1158/1078-0432.CCR-07-0330
  19. Siampanopoulou M, Galaktidou G, Dimasis N, Gotzamani-Psarrakou A (2013). Profiling serum HER-2/NEU in prostate cancer. Hippokratia, 17, 108-112.
  20. Siegel R, Naishadham D, Jemal A (2012). Cancer Statistics, 2012. CA Cancer J Clinicians, 62, 10-29. https://doi.org/10.3322/caac.20138
  21. Tambo M, Higashihara E, Terado Y, Nutahara K, Okegawa T (2009). Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer. Int J Urol, 16, 369-74. https://doi.org/10.1111/j.1442-2042.2009.02253.x
  22. Vickers AJ, Brewster SF (2012). PSA velocity and doubling time in diagnosis and prognosis of prostate cancer. Br J Med Surg Urol, 5, 162-8. https://doi.org/10.1016/j.bjmsu.2011.08.006

Cited by

  1. Platelet Derived Growth Factor-B and Human Epidermal Growth Factor Receptor-2 Polymorphisms in Gall Bladder Cancer vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5647
  2. Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6615
  3. The tumor marker Her-2/neu vol.68, pp.6, 2018, https://doi.org/10.1007/s40664-018-0265-x